多发性骨髓瘤 CAR-T 细胞治疗继发 Sweet 样综合征：1 例病例报告

Chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA CAR-T) has significantly improved outcomes in relapsed/refractory multiple myeloma (R/RMM), yet its spectrum of immune-related adverse events continues to be defined. Among these, cutaneous toxicities are not unusual, but frequently receive insufficient attention. Delayed-onset cutaneous reactions, in particular, may be underreported. CASE REPORT: We report a patient with R/RMM who achieved stringent complete response (sCR) following BCMA CAR-T therapy and developed delayed-onset cutaneous lesions on day 50 post-infusion. Histopathology revealed dense dermal neutrophilic infiltration, consistent with Sweet's syndrome. However, the patient lacked typical clinical features such as fever, arthralgia, or peripheral neutrophilia, prompting a diagnosis of 'Sweet-like syndrome' associated with CAR-T therapy. The lesions resolved spontaneously without systemic glucocorticoid therapy.

To our knowledge, virtually no cases of Sweet's syndrome or Sweet-like syndrome have been reported previously after BCMA CAR-T therapy, broadening the recognized spectrum of CAR-T-related cutaneous adverse events and underscoring the importance of early biopsy for atypical, delayed-onset rashes-rather than empiric systemic corticosteroid treatment-to guide appropriate management.